Скачать или смотреть Cellarity's AI-Powered Drug Discovery Platform: Revolutionizing Medicine

Cellarity, a biotechnology company, has published a groundbreaking framework in the journal Science, detailing its innovative approach to drug discovery. The company's platform integrates high-dimensional transcriptomics and AI predictive modeling to identify novel therapeutics for complex diseases. By focusing on the interplay of pathway connections and cellular states, Cellarity designs drugs that restore cellular function. The publication outlines a reproducible blueprint for integrating machine learning into drug discovery, addressing limitations of conventional methods. Cellarity's lead candidate, CLY-124, is in a Phase 1 clinical trial for sickle cell disease treatment. The company also releases open-source datasets for community engagement and model benchmarking, offering insights into cell states under chemical perturbation. This video explores Cellarity's cutting-edge technology and its potential to transform medicine.